Streetbeat News

Products Services

MAT

Mattel's CEO has expressed optimism about the potential of Mattel Films following the success of the Barbie movie, stating that it demonstrates the progress of their strategy to fully capitalize on their intellectual property.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 8:10 pm

MAT

Mattel's CEO has highlighted the upcoming Barbie movie as a demonstration of the company's intellectual property, its ability to attract top creative talent, and the capabilities of its franchise management organization.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 8:09 pm

KR

Kroger Health, a division of The Kroger Co., has launched a revamped version of its Kroger Health Savings Club Membership Program. The program aims to make medications more affordable and accessible for members and their families.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 7:46 pm

AMZN

NVDA

NVIDIA's H100 GPUs are now available on Amazon Web Services (AWS) Cloud, according to a Reuters report. This partnership could potentially boost the performance of cloud-based applications and services.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 7:37 pm

TMUS

VZ

Benchmark analyst Matthew Harrigan reiterated a Buy rating for T-Mobile US Inc (NASDAQ:TMUS) with a $200 price target. Harrigan sees T-Mobile as a relative haven if the current equity rally reverses. T-Mobile's customer momentum and long-term pricing are expected to benefit from a better network and superior value perception. The company is rolling out nationwide four-carrier aggregation for 5G, which should enhance its network capabilities. T-Mobile is also gaining traction in smaller and mid-sized markets, complementing its improved brand and network perception in urban areas.

Portfolio Pulse from Anusuya Lahiri

July 26, 2023 | 6:57 pm

INZY

Inozyme Pharma Inc (NASDAQ:INZY) has updated its global development strategy for INZ-701, a treatment for ENPP1 Deficiency, following meetings with the FDA and the European Medicines Agency's Paediatric Committee. The company plans to initiate the ENERGY-3 pivotal trial in October 2023 and aims to commercially launch INZ-701 for infant and pediatric patients by the second half of 2026. The company's cash balance of $140.2 million is expected to provide a cash runway into the first quarter of 2025. INZY shares are down 11.40% at $5.47.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 6:45 pm

AWKNF

Awakn Life Sciences Corp. (OTC:AWKNF) is moving closer to a Phase III clinical trial for the use of ketamine-assisted therapy to treat severe Alcohol Use Disorder (AUD). The company has also recently divested clinic assets in the UK to focus more on therapeutic research and intellectual property. The Phase III trial, which is the only one of its kind to receive government funding, will involve 280 participants and will be the largest of its kind.

Portfolio Pulse from The Dales Report

July 26, 2023 | 6:27 pm

ABT

Abbott Laboratories is recalling its Amplatzer Steerable Delivery Sheath due to an increased risk of air embolism in patients. The company has reported 26 incidents and 16 injuries related to this issue, but no deaths. Abbott has issued a Medical Device Recall notice and is recalling 672 devices distributed between October 2022 and February 2023. The company's shares are up 0.89% at $113.95.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 6:20 pm

AI

C3 AI will begin its presentation on 'Decision Advantage with Generative AI for Defense' on July 26 at 11 Pacific Daylight Time. The presentation will be available online.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 6:14 pm

EDBL

Edible Garden has received a Notice of Allowance for a U.S. patent titled 'Greenhouse Agriculture System'. The patent application can be found on the U.S. Patent and Trademark Office's website.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 5:40 pm